Disclosures for "Epilepsy-related and All-cause Healthcare Resource Utilization After Initiation of Adjunctive Cenobamate"
-
Dr. Klatte has received personal compensation in the range of $0-$499 for serving as a Consultant for SK Life Science . Dr. Klatte has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis, Inc. Dr. Klatte has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurelis.
-
Mr. Stern has received personal compensation for serving as an employee of SK Life Science.
-
Dr. Kamin has received personal compensation for serving as an employee of SK LIFE SCIENCE INC.
-
Clarence Wade has nothing to disclose.
-
Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Lifesciences. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Kerr has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for QurAlis. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. The institution of Dr. Kerr has received research support from NINDS. The institution of Dr. Kerr has received research support from American Epilepsy Society. The institution of Dr. Kerr has received research support from American Academy of Neurology. The institution of Dr. Kerr has received research support from SK Life Science. The institution of Dr. Kerr has received research support from Biohaven Pharmaceuticals. Dr. Kerr has received publishing royalties from a publication relating to health care.